MXPA96005253A - An injectable analgesic therapeutic therapeutic composition, for administration intramuscu - Google Patents
An injectable analgesic therapeutic therapeutic composition, for administration intramuscuInfo
- Publication number
- MXPA96005253A MXPA96005253A MXPA/A/1996/005253A MX9605253A MXPA96005253A MX PA96005253 A MXPA96005253 A MX PA96005253A MX 9605253 A MX9605253 A MX 9605253A MX PA96005253 A MXPA96005253 A MX PA96005253A
- Authority
- MX
- Mexico
- Prior art keywords
- weight
- volume
- analgesic
- injectable
- further characterized
- Prior art date
Links
- 230000000202 analgesic Effects 0.000 title claims abstract description 26
- 230000001225 therapeutic Effects 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 34
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000965 nimesulide Drugs 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims abstract description 7
- 239000003623 enhancer Substances 0.000 claims abstract description 4
- 230000002708 enhancing Effects 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 36
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 22
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- 229960002903 benzyl benzoate Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 9
- 229940093471 ethyl oleate Drugs 0.000 claims description 9
- 229940049964 Oleate Drugs 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 5
- 230000003078 antioxidant Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- SDIXRDNYIMOKSG-UHFFFAOYSA-L Disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 3
- -1 dimet amide amide Chemical class 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- 229940075579 Propyl Gallate Drugs 0.000 description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- LOYINFBFPXYKQD-UHFFFAOYSA-N 2-butyl-3-methoxyphenol Chemical compound CCCCC1=C(O)C=CC=C1OC LOYINFBFPXYKQD-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- LDZLXQFDGRCELX-UHFFFAOYSA-N 4-phenylbutan-1-ol Chemical compound OCCCCC1=CC=CC=C1 LDZLXQFDGRCELX-UHFFFAOYSA-N 0.000 description 1
- 208000005298 Acute Pain Diseases 0.000 description 1
- 208000004120 Athletic Injury Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N Ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229960001295 Tocopherol Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to a therapeutic, analgesic, injectable pharmaceutical composition for intramuscular administration, characterized in that it comprises the following ingredients: 1. Nimesulide: 2.5% to 10% weight / volume; 2. Parenteral absorption enhancer vehicle / base: 90 to 97.5% by weight / volume
Description
AN INJECTABLE ANALGESIC THERAPEUTIC THERAPEUTIC COMPOSITION, FOR INTRAMUSCULAR ADMINISTRATION
The present invention relates to a novel, analgesic, injectable therapeutic pharmaceutical composition containing Nimesulide, which is N ~ (4-n? Tro-2-pheoxifene) -met nsulfonamide, for intramuscular administration; and to a process for its preparation.
BACKGROUND OF THE INVENTION
The use of Mirnesulide median * and intramuscular admiration, as an analgesic agent, has not been successful because Nirnesuli is practically water soluble and its formulations in conventional oily bases, or as suspensions, result in the formation of deposits in the muscular tissues, which hinder the main objective of obtaining rapid relief. The market and bibliographic investigations do not show any report about a parenteral dosage form of Nirnesulide (Drugs, 48 (3) 431-454- J 994). An injectable formulation of Nimesu ide has been reported in the prior art (patent of fCP No. 10 9 * 5/34533) which uses a Nunesulide salt form (Nirnesul j de-L-lisin) formed on the basis of ci clodox iñas It was reported that the maximum solubility obtained was 2.4 mg / rnl, which is not suitable for an intramuscular injection, since very large volumes would be required to administer therapeutic doses. The reported oral dose of Nimesulide varies between 100 and 400 mg per day. If one takes into account that the intramuscular dose is half the oral dose, it would be necessary to inject 50 mg of the drug, which would require approximately 20 l of the solution described in the prior art, that is, WO 95/34533. On the contrary, in the present invention there is reported a formulation for intramuscular injection of Nimesulide, which incorporates the original drug molecule in a suitable base, having a concentration of 50 mg / ml. With this formulation, therapeutically effective doses of NimesuJide can be conveniently administered. Additionally, the present invention gives the flexibility to inject 0.4 mi to 3,. L) rnl of the 50 mg / ml solution as required for the two ication. The present invention utilizes solubilization techniques to achieve such high concentrations of Nunesulide and salt forms and complexing agents were not used, as reported in the prior art. It is an object of the present invention to provide a novel, injectable, analgesic therapeutic composition containing Ni esulide for intramuscular administration, from which Nimesulide is rapidly absorbed and rapidly impregnated in body fluids. It is another object of the present invention to provide a method for the preparation of the novel injectable analgesic therapeutic composition containing Nirnesulide, according to the present invention, for mtmuscular administration.
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides an innovative injectable analgesic therapeutic pharmaceutical composition for intramuscular administration; wherein said composition comprises: 1. Nimesulide: 2.5% to 10% by weight / volume 2. Parenteral absorption vehicle / ba ncrementor:: 90 to 97.5% by weight / volume Said parenteral absorption enhancer base vehicle comprises: Dimethylacetamide: 5 to 12% by weight / vol men
2. Benzoate Benzoate: 20 to 50% in pe / Lumen
3. Benzyl alcohol: 0 to 10% w / v 4 .. Ethyl oleate: 30 to 65% w / v. According to a preferred embodiment of the present invention, the novel injectable analgesic therapeutic composition comprises: NirnesulLde 5% in weight / volume? ., Dimethylacetamide 10% by weight / volume 3. Benzyl benzoate 40% by weight / volume 4 »Benzyl alcohol 2% by weight / volume 5. Oleate of 30% at ñ5% by weight / volume,
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a novel, injectable therapeutic, analgesic pharmaceutical composition for intramuscular administration, wherein the composition comprises: L. Nimesulide 2.5% to 10% w / v
2. Vehicle / base absorption increaser μa in e - ral 90% to 97.5% in weight / volume,
Said parenteral absorption enhancer vehicle / base comprises: 1. dune »isolacet measures 5 to 12% w / v
2. benzyl benzoate 20 to 50% by weight / v? lumen
3. benzyl alcohol 0 to L0% by weight / vo Lumen 4 .. olea or of etio 30 to 65% by weight / volume. According to a preferred embodiment of the present invention, the novel injectable analgesic therapeutic composition comprises 1"Ni esulide: 5% by weight / vo 1 urnen 2. dimet amide amide: 10% by weight / volurnen 3. benzyl benzoate: 40% by weight / volume 4. benzyl alcohol: 2% by weight / volume 5. oleate et. Lio: 30 to 65% by weight / volume According to another preferred embodiment of the present invention, the ethyl benzoate is partially replaced by 5% to 10% by weight / volurnen of the Cremophor EL (cast polyoxyethylene glycol castor oils). In accordance with another preferred embodiment of the present invention, a conventionally known antioxidant, such as ascorbyl pal or ascorbyl, hydroxybutyl aniso, is added to the injectable analgesic composition. , hadroxybutyl toluene, propyl gallate and f - tocopherol. The present invention also provides a method for the preparation of the injectable analgesic therapeutic composition, according to the present invention; wherein said process comprises the following steps: (a) from 5% to 12% by weight / volume of dimethyacetamide and from 20% to 50% by weight / volume of benzylol benzoate is mixed in a vessel equipped with an agitator. low speed (l, 000 to L, 500 rpm) and added from 1% to 7% weight / volume of N mesuL, and stirred until completely dissolved;
(b) 0% to 10% w / v% of benzyl alcohol and a portion of 30% to 65% w / v% oleate oleate are mixed in a vessel equipped with a stirrer. () Obtain the mixture obtained in step (a) from the mixture obtained in step (b), with slow stirring, and bring the volume of the obtained mixture to 100 ml with the rest of the amount of oleate of ethyl, which results in the preparation of the desired injectable analgesic composition. According to a preferred embodiment of the process according to the present invention, in step (a) of the above-mentioned process, 10% w / v of dinethylaceta-ida and 40% by weight / volume of benzyl benzoate are mixed; and 5% by weight / voiurnen of Ninesulide is added to it. In step (b) of said process, 2% by weight / volurnen of benzyl alcohol and a portion of 30% to 65% by weight / voiurnen of ethyl oleate are mixed. Preferably, step (c) of said process is carried out under continuous flooding with nitrogen, and the resultant solution, obtained, is passed through a nylon membrane filter of 0.22 u. According to another preferred embodiment of the present invention, a conventionally known antioxidant, such as ascorbyl palmitate, hydroxy butylanisol, hydroxypropyl toluene, propyl gallate, is added to said analgesic injectable composition when it is prepared. to the facto oco ferol. The present invention is exemplified by the following examples for the preparation of the injectable analgesic composition.
EXAMPLE I
(a) 10 g of dirnethylaceta-ida and 40 g of benzyl benzoate are mixed in a vessel equipped with a low-speed stirrer (1,000 to 1,200 rpm) at a temperature between 25 ° C and 30 ° C. 5 g of Nimesulide is added in small increments and stirred until completely dissolved. (h) 10 g of Cre oμhor FL and an amount of otyl oleate are mixed in a vessel equipped with a stirrer at room temperature. (c) The mixture obtained in step (a) is added to the mixture obtained in step (-b) under slow stirring, and is stirred for about 30 minutes. The volume is brought to 100 ml with ethyl oleate and filtered through a 0.22 u nylon membrane filter to sterilize it.
EXAMPLE II
(a) 20 g of dimeti lacetarnide and 76 g of benzyl benzoate are mixed in a vessel equipped with a ba stirrer at speed, at a temperature between? 5 ° C and 30 ° C. To the obtained mixture 10 g of NirnesulLde is added in small amounts each time, and it is stirred until it dissolves completely. (b) g of benzyl alcohol and an amount of ethyl oleate are mixed in a vessel equipped with a stirrer at ambient temperature.
(c) The mixture obtained in step (a) is added to the mixture obtained in step (b), with slow stirring, and stirred for about 30 minutes. The volume is brought to 200 rnl with ethyl oleate and filtered through a 0.22 u nylon membrane filter to sterilize it. The injectable analgesic composition, according to the present invention, in preliminary animal analyzes and preclinical analysis, has shown to possess remarkable analgesic activity. Odi cyonally, it has been found that it is not toxic, not even by repeated applications in the same place. No incidence of tissue necrosis or any other side effect was observed. The analgesic dose ranges from 0.15 mg / kg to 8.4 mg / kg. This analgesic composition is very effective and useful for the treatment of acute pain conditions, such as post-operative trauma, pain associated with cancer, sports injuries and the like. It was found that the analgesic activity of the composition Therapeutics prepared in accordance with the present invention were dose dependent and passed the tests of subacute toxicity and undue toxicity. Preclinical toxicology studies showed values of LD50 - 129.55 mg / kg, DE50 - 3 rng / kg with a therapeutic index - 43.13 in mice. This demonstrates high safety for the present invention. The injectable analgesic therapeutic composition, according to the present invention, is not a simple mixture, but has different properties with respect to the sum total of the properties of its ingredients, as noted hereinabove. Since many apparently different embodiments of the present invention could be made, without departing from the spirit or scope thereof, it is intended that the description of the invention given herein be interpreted solely as illustrative and in no way as a limitation.
Claims (5)
1. Dinethylacetanide: 10% by weight / volurne 2. Benzyl benzoate: 40% by weight / volume 3. Benzyl alcohol: 2% by weight / volume 4. Ethyl oleate: 30% to 65% by weight / vol. 4. A pharmaceutical composition according to claim 3, further characterized in that the benzyl benzoate used is partially replaced with 5% to 10% w / v of Cre ophor FL. 5. A pharmaceutical composition according to claim 1, further characterized in that a conventionally known antioxidant is added to the composition, such as those described herein. 6. A therapeutic, analgesic, injectable pharmaceutical composition for intramuscular administration, characterized in that it comprises: i. Nirnesulide: 2.5% to 10% by weight / volurnen
2. dimet i lacetamide: 5 to 12% by weight / volurnen
3. Benzoyl benzoate: 20 to 50% by weight / volume
4. Benzyl alcohol: 0 to 10% by weight / volume
5. Ethyl oleate: 30 to 65% by weight / volume. 7. A procedure for the preparation of an analgesic therapeutic composition, injectable, novel, containing Nimesulide, for mthral muscle administration, characterized because it comprises the following steps: (a) 5% is mixed 12% by weight / volume of dirnet and Lacet amide and from 20% to 50% by weight / volume of benzoate benzoate, in one fraction and added from 3% to 7% in volume / volume (j Nimes? lide, and shake until it is completely dissolved; (b) it is mixed separately from 0% to 10% w / v of benzyl alcohol and a portion of 30% to 65% w / v. oleate of et i lo; (c) The mixture obtained in step (a) is added to the mixture obtained in step (b), with slow stirring, which results in the preparation of the desired injectable analgesic composition. 8. The process according to claim 6, further characterized in that step a) is mixed 10% by weight / volume of dimethylacetamide and 40% by weight / volume of benzyl benzoate; and 5% by weight / volurnen of Nirnesuli is added e. 9. The process according to claim 6, further characterized in that, in step b), 2% by weight / volume of benzyl alcohol and a portion of 30% to 65% by weight / volume of ethyl oleate are mixed. . 10. The process according to claim 6, further characterized in that the benzyl benzoate used in step (a) is partially replaced with 5% to 1.0% w / v of Cremophor HE. 1.1.- The method according to claim 6, further characterized in that an antioxidant conventionally known, as described herein, is added to the injectable analgesic composition, when it is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX9605253A MX9605253A (en) | 1996-10-30 | 1996-10-30 | An injectable analgesic therapeutic pharmaceutical composition, for intramuscular administration. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX9605253A MX9605253A (en) | 1996-10-30 | 1996-10-30 | An injectable analgesic therapeutic pharmaceutical composition, for intramuscular administration. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MXPA96005253A true MXPA96005253A (en) | 1998-04-01 |
| MX9605253A MX9605253A (en) | 1998-04-30 |
Family
ID=39427803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9605253A MX9605253A (en) | 1996-10-30 | 1996-10-30 | An injectable analgesic therapeutic pharmaceutical composition, for intramuscular administration. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX9605253A (en) |
-
1996
- 1996-10-30 MX MX9605253A patent/MX9605253A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2188703C (en) | Therapeutic injectable analgesic pharmaceutical composition containing nimesulide 4-nitro, 2-phenoxyphenyl methane sulphonamide for intramuscular administration | |
| DE69722580T2 (en) | NEW STABLE LIQUID PARACETAMOL AGENTS AND METHOD FOR THE PRODUCTION THEREOF | |
| KR960005705B1 (en) | Pharmaceutical composition of florfenicol | |
| EP3056200B1 (en) | Huperzine for use in treating seizure | |
| US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
| KR20080016689A (en) | Novel injectable compositions and process for preparation of such compositions | |
| CN109562281A (en) | The prodrug of phenols TRPV1 agonist is combined with local anesthetic and vasoconstrictor for improving local anaesthesia | |
| EP3581169A1 (en) | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief | |
| JPH064534B2 (en) | Combination drug for long-term pain relief | |
| JPH02207018A (en) | Skin drug for external use | |
| CN115804771A (en) | Lipid drug delivery system with long-acting sustained release effect and preparation method thereof | |
| MXPA96005253A (en) | An injectable analgesic therapeutic therapeutic composition, for administration intramuscu | |
| KR20200018438A (en) | Drug-Containing Formulations of Improved Solubility | |
| KR20040062982A (en) | Transdermal drug delivery system of strychnine, brucine, securinine and their salts | |
| AU2001235489B2 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| KR101153250B1 (en) | Glycyrrhizin high-concentration preparation | |
| CN112891303A (en) | Pregabalin oral solution and preparation method thereof | |
| RU2141845C1 (en) | Pharmaceutical composition of analgetic agent and method of its preparing | |
| KR101805087B1 (en) | Non-aqueous Oily Injectable Formulation Exhibiting Preservative Efficacy | |
| KR100215194B1 (en) | Novel therapeutic injectable analgesic pharmaceutical composition containing nimesulide 4-nitro, 2 phenoxyphenyl methane sulphonamide for intramuscular administration | |
| CA2542509A1 (en) | Salts of pharmacologically active compounds | |
| DE69629919T2 (en) | Injectable compositions containing nimesulides | |
| WO2011135073A1 (en) | Adhesive slow-release formulations for the local administration of curcumin | |
| BG63271B1 (en) | New therapeutical injection-type analgetic pharmaceutical composition containing nimesulid (4-nitro, 2-phenoxyphenylmetanesulphonamide) for intramuscular administration and method for its preparation | |
| AU747416B2 (en) | Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt |